The Surprising Conflict at the Heart of Trump’s Surgeon General Pick

The nomination of Dr. Nicole Saphier for surgeon general has raised eyebrows not just because of her qualifications or politics, but also due to a closer look at her supplement business. As a radiologist specializing in breast cancer at Memorial Sloan Kettering Cancer Center, Saphier has built a reputation as an outspoken advocate for women’s health. However, her side hustle selling dietary supplements under the brand Drop RX raises questions about her ability to serve as America’s doctor.

The products in question contain ingredients that have been banned by the Pentagon and warned against by health experts. Kava kava root is the key component of Drop RX’s “Calm” formulation, which has been linked to liver damage and was explicitly prohibited by the US military in 2024 due to concerns about impairment and readiness.

The Pentagon’s decision to ban kava was a serious one, made after careful consideration of its potential risks. In contrast, Saphier’s company sells these supplements with unsubstantiated claims and vague language that could easily confuse consumers.

Saphier’s credibility as a medical professional is at stake. As America’s doctor, she would be responsible for communicating evidence-based information to the public, not peddling unproven remedies. The surgeon general is expected to uphold the highest standards of scientific rigor and transparency.

The White House has defended Saphier’s nomination, citing her expertise in breast cancer prevention and her “outspoken voice” on various health issues. However, this defense rings hollow when confronted with evidence of her supplement business. Can we really trust someone who profits from selling unproven remedies to be a champion of science?

Critics like Dr. Peter Lurie have long warned about the dangers of loosely regulated supplements, often peddled by individuals with little concern for evidence or safety. This is precisely what has unfolded in this case.

Amazon is investigating Drop RX’s compliance with its policies on supplement sales. It’s essential to remember that this isn’t just a matter of business practices; it’s about trust and accountability in the medical community. What message does Saphier’s nomination send to healthcare professionals? Is it acceptable to profit from selling unproven remedies while holding public office?

The consequences of this situation go beyond Saphier herself, speaking to a broader culture of pseudoscience and lack of transparency in the wellness industry, as well as the ongoing politicization of science. What does this mean for the future of medical research and policy? Will we continue to see politicians and healthcare professionals profit from questionable supplement sales?

The answer to these questions will depend on how this situation unfolds. One thing is certain: Dr. Nicole Saphier’s nomination has exposed a disturbing conflict at the heart of Trump’s administration, one that threatens the very credibility of America’s doctor.

Ultimately, it’s not just about Saphier or her supplement business; it’s about what kind of role model we want for our nation’s health. We need a surgeon general who is guided by evidence and committed to transparency, not someone who profits from selling unproven remedies under the guise of “wellness.” The fate of this nomination hangs in the balance, but one thing is clear: we can’t afford another embarrassment like this in the administration.